STO-609

N/A

Report date: 2024/10/25 10:24:41
NME

Base Information

Drug NameSTO-609
Drug Alias NameSTO-609
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcium/calmodulin-dependent protein kinase kinase 1 inhibitorsCalcium/calmodulin-dependent protein kinase kinase 2 inhibitors
TargetsCalcium/calmodulin-dependent protein kinase kinase 1Calcium/calmodulin-dependent protein kinase kinase 2
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSumitomo Chemical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSumitomo Chemical Co Ltd
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A